Doctor of Pharmacy

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Retrieved on: 
Monday, April 8, 2024
Retina, Amgen, Organization, Regeneron Pharmaceuticals, Doctor of Pharmacy, Chiron Corporation, Patient, ISTA Pharmaceuticals, Bayer, Shore, AMD, Ophthalmology, Pharmaceutical industry

Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team.

Key Points: 
  • Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team.
  • Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- and post-launch initiatives for medicines in ophthalmology and retinal disease.
  • Over the course of his career, Dr. Han has served in senior leadership positions in medical and scientific affairs at leading biopharmaceutical companies.
  • He joins Opthea from Adverum Biotechnologies, Inc. where he led the development of the Medical Affairs function.

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Retrieved on: 
Monday, April 8, 2024
Doctor of Pharmacy, Progression-free survival, Patient, Journal, Oncology, Standard of care, Woman

“Fully enrolling ROSELLA takes us a big step closer to addressing the unmet medical need of women with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “Fully enrolling ROSELLA takes us a big step closer to addressing the unmet medical need of women with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “Relacorilant has the potential to become the standard of care for patients with this devastating disease.
  • The ROSELLA trial enrolled 381 women at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia.
  • Patients were randomized 1:1 to receive either relacorilant dosed intermittently with nab-paclitaxel or nab-paclitaxel monotherapy.

MannKind Repays Certain Debt Obligations

Retrieved on: 
Wednesday, April 3, 2024
MannKind Corporation, Note, Professional corporation, Patient, Loan agreement, Loan, Doctor of Pharmacy, Security (finance)

On April 1, 2024, MannKind made a payment to the lenders under the Loan Agreement of approximately $31.6 million, including a contractually obligated exit fee of $2.8 million and a prepayment fee of approximately $0.3 million, in full satisfaction of all of the Company’s debt obligations under the Loan Agreement, which would have matured on August 1, 2025.

Key Points: 
  • On April 1, 2024, MannKind made a payment to the lenders under the Loan Agreement of approximately $31.6 million, including a contractually obligated exit fee of $2.8 million and a prepayment fee of approximately $0.3 million, in full satisfaction of all of the Company’s debt obligations under the Loan Agreement, which would have matured on August 1, 2025.
  • In connection with the repayment of outstanding indebtedness by MannKind, all liens, mortgages and security interests in any assets or property securing the obligations under the Loan Agreement were automatically terminated and released and MannKind and its subsidiaries were automatically released from all guarantees.
  • Upon receipt of this consideration, all indebtedness under the Note was satisfied in full and all obligations under the Note were automatically terminated.
  • “Repaying the MidCap loan agreement eliminates our most expensive debt going forward and releases our assets from their security interests,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation.

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

Retrieved on: 
Monday, April 1, 2024
Death, Adenoma, Doctor of Pharmacy, Risk, Patient, Oncology, Syndrome, Hyperglycemia, Hyperplasia, Hypertension, Pharmaceutical industry

“Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “GRADIENT is the first prospective placebo-controlled study to be conducted exclusively in these patients with Cushing’s syndrome.
  • We expect data from GRADIENT in the fourth quarter of this year.”
    GRADIENT is a randomized, double-blind, placebo-controlled trial conducted at sites in the United States, Europe and Israel.
  • One-hundred thirty-seven patients were randomized 1:1 to receive relacorilant or placebo for 22 weeks.

American Oncology Network Announces Attendance and Participation at Leading Community Oncology Conference

Retrieved on: 
Thursday, March 28, 2024
Community, AON, CSSBB, Growth, Doctor of Pharmacy, Health, Partnership, Education, Patient, Knowledge, Cancer, COA, Hope, Matter, Personalized medicine, Community Oncology Alliance, MD, Privacy, Competition, MBA, Confidentiality, Pharmacy, Physician, Medicine, Pharmaceutical industry

FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.

Key Points: 
  • FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.
  • Since its inception, AON has provided administrative support and access to critical offerings such as the in-house pharmacy and laboratory services to independent oncology medical practices.
  • The conference brings together today’s healthcare and community oncology leaders for two days of education and networking.
  • We understand the future of healthcare is a collective effort, and the conference provides a platform to foster unity and the exchange of information.

Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230

Retrieved on: 
Wednesday, March 27, 2024
OS, Harvard Medical School, DOI, Radium-223, Prostate cancer, Gene expression, Metastasis, Doctor of Pharmacy, JCO, Assistant, Patient, Tap, Biomarker, RNA, Chinese, Quality of life, CRPC, Senior, Hospital, Prognosis, CTC, Radiation therapy, PSA, FDA, CTCM, Medical imaging

ANDOVER, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223. The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230).

Key Points: 
  • The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230 ).
  • “Radium-223 is a valuable treatment option for patients with mCRPC, but better biomarkers are needed to identify patients most likely to benefit from therapy.
  • Additionally, imaging assessment in patients with bone-predominant disease has also been limited in patients receiving radium-223.
  • Upon controlling for known prognostic markers, PSA and tAP, the presence of baseline CTC AR-V7 expression was most predictive of OS among patients receiving radium-223.

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

Advancing Health Equity Through Pharmacy: New White Paper Explores the Pivotal Role Pharmacists Can Play in Providing Needed Care for Underserved Patients

Retrieved on: 
Tuesday, April 9, 2024
Don Miguel Ruiz, Pharmacist, Health, Health literacy, Doctor of Pharmacy, Patient, Policy, Asthma, Health equity, Physician, Medicine, Pharmaceutical industry

The new paper explores the barriers impacting patient health, particularly for under-resourced patients and those on Medicaid, and how pharmacists can bridge healthcare gaps and improve the health of those individuals.

Key Points: 
  • The new paper explores the barriers impacting patient health, particularly for under-resourced patients and those on Medicaid, and how pharmacists can bridge healthcare gaps and improve the health of those individuals.
  • The report also proposes steps needed to further elevate the role of pharmacists to help reduce disparities by increasing the services and care they can provide.
  • Value-based practices, like AbsoluteCare , that integrate pharmacists into the healthcare team, can improve patient adherence and outcomes in vulnerable populations.
  • "We have seen significant patient improvements when pharmacists intervene and educate our members about their health and treatments," said Mike Radu, CEO, AbsoluteCare.

Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Brain, Dementia, Growth, Doctor of Pharmacy, LMI, Deficit spending, Partnership, Patient, PET, Research, Radiopharmaceutical, Drug development, FDA, Physician, Medical imaging

BOSTON, April 5, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Cleveland, Ohio. The first doses have been made available on April 4, 2024.

Key Points: 
  • BOSTON, April 5, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE's radiopharmaceutical manufacturing site located in Cleveland, Ohio.
  • "By adding Cleveland to our distribution network, Life Molecular Imaging is thrilled to provide additional availability of Neuraceq®, an important imaging tool for the detection of beta-amyloid plaques in the brain.
  • Brian Schumer, PharmD, SOFIE COO states, "We are excited to bring Neuraceq® availability to another SOFIE network site.
  • SOFIE is committed to the further expansion and availability of LMI's Neuraceq® PET diagnostic tracer throughout our national PET manufacturing and dispensing network."

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, March 25, 2024
Patient, Cancer, Doctor of Pharmacy, PCSA, Safety

HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.

Key Points: 
  • HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.
  • David Young, PharmD, Ph.D., President of Research and Development at Processa, will be available during the allotted times below and, along with Processa CEO George Ng, will be available for 1-on-1 meetings.
  • The following posters will be presented: